Pharmacotherapy for excessive daytime sleepiness.

Area of Science:

• Neurology
• Pharmacology
• Sleep Medicine

Background:

• Excessive daytime sleepiness (EDS) has significant negative impacts on daily functioning, including safety and work performance.
• Causes of EDS are diverse, ranging from sleep deprivation and fragmentation to neurological and psychiatric disorders.
• Traditional treatments for EDS, like sympathomimetic psychostimulants, have limitations.

Purpose of the Study:

• To review the therapeutic options for excessive daytime sleepiness (EDS).
• To evaluate the role of modafinil as a treatment for EDS.
• To discuss potential new indications for wakefulness-promoting agents.

Main Methods:

• Literature review of studies on EDS treatments.
• Analysis of the efficacy and safety profiles of traditional stimulants and modafinil.
• Exploration of emerging applications for wakefulness promoters.

Main Results:

• Modafinil presents a safer side-effect profile compared to older stimulant medications.
• Interest in modafinil for EDS management in various conditions, including narcolepsy and obstructive sleep apnea, is growing.
• Evidence for the use of wakefulness promoters in healthy adults is currently insufficient.

Conclusions:

• Modafinil is a promising therapeutic option for EDS with a favorable safety profile.
• Further randomized controlled trials are needed to confirm the long-term efficacy and safety of modafinil for expanded indications.
• The use of wakefulness promoters in healthy adults for sustained operations is not yet justified based on current evidence.